瘤内SD-101联合帕博利珠单抗治疗晚期黑色素瘤的Ib期多中心研究结果
这项Ib期多中心试验评估瘤内注射SD-101(一种刺激TLR9的合成CpG寡核苷酸)联合帕博利珠单抗治疗不可切除或转移性黑色素瘤。常见不良事件为注射部位反应和短暂轻中度流感样症状。抗PD-1初治9例患者ORR为78%,12个月PFS率88%,OS率89%;既往抗PD-1治疗13例患者ORR为15%。
要点
- 瘤内SD-101联合帕博利珠单抗耐受性良好,主要不良反应为注射部位反应和短暂流感样症状。
- 抗PD-1初治患者ORR达78%,12个月PFS率88%,OS率89%。
- 既往抗PD-1治疗患者ORR为15%,提示联合方案在耐药人群疗效有限。
核心结论
- 瘤内SD-101联合帕博利珠单抗耐受性良好,可在肿瘤微环境诱导广泛免疫激活,并在外周和内脏病灶产生持久肿瘤缓解。
研究设计与样本
- Ib期多中心试验,评估瘤内SD-101联合帕博利珠单抗治疗不可切除或转移性黑色素瘤。
- 抗PD-1初治患者9例,既往接受过抗PD-1治疗患者13例。
主要发现
- 抗PD-1初治9例患者ORR为78%,估计12个月PFS率88%,OS率89%。
- 既往抗PD-1治疗13例患者ORR为15%。
- 肿瘤活检RNA分析显示CD8+ T细胞、自然杀伤细胞、细胞毒性细胞、树突状细胞和B细胞增加。
临床怎么用
- 联合方案可用于抗PD-1初治晚期黑色素瘤患者,需关注注射部位反应和流感样症状。
- 对既往抗PD-1治疗失败患者,该联合方案单药疗效有限,需考虑其他策略。
局限性
- 为早期Ib期小样本研究,抗PD-1初治9例、经治13例,结论需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PD-1 inhibitors are approved for treating advanced melanoma, but resistance has been observed. This phase Ib trial evaluated intratumoral SD-101, a synthetic CpG oligonucleotide that stimulates Toll-like receptor 9 (TLR9), in combination with pembrolizumab in patients with unresectable or metastatic malignant melanoma. The most common adverse events related to SD-101 were injection-site reactions and transient, mild-to-moderate "flu-like" symptoms. Among the 9 patients naïve to anti-PD-1 therapy, the overall response rate (ORR) was 78%. The estimated 12-month progression-free survival rate was 88%, and the overall survival rate was 89%. Among 13 patients having prior anti-PD-1 therapy, the ORR was 15%. RNA profiling of tumor biopsies demonstrated increased CD8+ T cells, natural killer cells, cytotoxic cells, dendritic cells, and B cells. The combination of intratumoral SD-101 and pembrolizumab was well tolerated and induced broad immune activation in the tumor microenvironment with durable tumor responses in both peripheral and visceral lesions.Significance: These early data demonstrate that the combination of pembrolizumab with intratumoral SD-101 is well tolerated and can induce immune activation at the tumor site. Combining an intratumoral TLR9 innate immune stimulant with PD-1 blockade can potentially increase clinical efficacy with minimal additional toxicity relative to PD-1 blockade alone. Cancer Discov; 8(10); 1250-7. ©2018 AACR. This article is highlighted in the In This Issue feature, p. 1195.
引用
- Ribas A, Medina T, Kummar S, et al. SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study. Cancer Discov. 2018. PMID: 30154193. doi:10.1158/2159-8290.CD-18-0280
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。